Study guide
4.1 Upper Gastrointestinal Bleeding & Dyspepsia
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
4.1 Upper Gastrointestinal Bleeding & Dyspepsia
Key Takeaways Explain This Topic AI
Acute upper gastrointestinal bleeding originates proximal to the ligament of Treitz; initial resuscitation requires two wide-bore cannulae, blood cross-matching, and a restrictive transfusion threshold of Hb below 70 g/L with a target of 70–90 g/L (threshold 80 g/L, target 80–100 g/L with acute coronary syndrome).
The Glasgow-Blatchford Score risk-stratifies patients before endoscopy (NICE: consider early discharge at a score of 0; BSG: outpatient management at 0–1), whereas the full Rockall Score assesses post-endoscopy rebleeding and mortality risk.
Suspected variceal haemorrhage mandates immediate pre-endoscopic medical resuscitation with intravenous terlipressin (2 mg bolus) and broad-spectrum antibiotic prophylaxis (ceftriaxone) before urgent therapeutic endoscopy within 24 hours.
Non-variceal peptic ulcer bleeding requires dual-modality endoscopic haemostasis (adrenaline injection plus clips or thermal coagulation) followed by high-dose IV proton pump inhibitor therapy.
NICE NG12 recommends urgent direct-access endoscopy (within 2 weeks) for dysphagia, or age ≥55 with weight loss plus upper abdominal pain, reflux or dyspepsia; H. pylori eradication utilizes 7-day triple therapy comprising a PPI, amoxicillin, and clarithromycin (or metronidazole).
Last updated: October 2026
Upper Gastrointestinal Bleeding & Dyspepsia
Acute upper gastrointestinal bleeding (UGIB) is defined as intraluminal haemorrhage arising proximal to the ligament of Treitz (the suspensory muscle of the duodenum). In the United Kingdom, UGIB accounts for approximately 50 to 70 hospital admissions per 100,000 adults annually, carrying an overall inpatient mortality of 8% to 10%. Clinical success hinges on rapid hemodynamic resuscitation, accurate pre-endoscopy risk stratification, timely pharmacological intervention, and urgent therapeutic endoscopy.
1. Clinical Presentation & Differential Aetiology
UGIB classically presents with:
Haematemesis: Vomiting of frank bright red blood or dark "coffee-ground" altered blood (haematin produced by gastric acid oxidation).
Melaena: Passage of black, tarry, foul-smelling stools resulting from bacterial degradation of haemoglobin over transit through the small and large bowel.
Haematochezia: Brisk passage of fresh red rectal blood, typically seen in massive, exsanguinating upper GI haemorrhage accompanied by hemodynamic shock.
Aetiology Frequency Key Clinical Features & Pathophysiology
Peptic Ulcer Disease (PUD) ~50% Duodenal ulcers (more common, posterolateral wall eroding into the gastroduodenal artery) or gastric ulcers (lesser curvature eroding into the left gastric artery). Strongly linked to Helicobacter pylori and NSAID use.
Oesophageal & Gastric Varices ~10–15% Massive, painless haematemesis in patients with liver cirrhosis, portal hypertension, or chronic alcohol misuse. Highest case-fatality rate (~15–20% mortality per bleeding episode).
Mallory-Weiss Tear ~5–10% Longitudinal mucosal laceration at the gastro-oesophageal junction caused by forceful retching or vomiting, classically following acute alcohol binging. Bleeding is typically self-limiting.
Gastric Neoplasm ~3–5% Insidious blood loss or coffee-ground vomiting accompanied by systemic "red flag" features: anorexia, profound early satiety, and progressive cachexia.
Erosive Gastritis / Duodenitis ~10–15% Superficial mucosal inflammation caused by high-dose NSAIDs, severe physiological stress (Curling's ulcers in burns, Cushing's ulcers in head trauma), or alcohol.
Dieulafoy Lesion ~1–2% Large, tortuous submucosal arteriole that erodes through mucosal surface without surrounding ulceration, typically in the gastric fundus; causes intermittent, massive arterial spurting.
Boerhaave Syndrome <1% Transmural oesophageal perforation following violent emesis; presents with severe retrosternal and epigastric pain, surgical emphysema, and sepsis (Mackler's triad: vomiting, chest pain, subcutaneous emphysema). Surgical emergency.
2. Emergency Resuscitation & Transfusion Strategy
Initial resuscitation must proceed according to the systematic ABCDE algorithm :
Vascular Access: Immediately insert two large-bore peripheral intravenous cannulae (14G or 16G) into the antecubital fossae. Central venous access should not delay peripheral wide-bore cannulation.
Urgent Blood Sampling: Full blood count, urea and electrolytes (U&Es), liver function tests, coagulation screen (INR, prothrombin time, fibrinogen), and cross-match for 2 to 4 units of packed red blood cells (or activate the local hospital Major Haemorrhage Protocol if massive bleeding and hemodynamic instability are present).
Biochemical Hallmark: The urea-to-creatinine ratio is characteristically disproportionately elevated. Digestion and intestinal absorption of blood proteins, combined with hypovolaemic prerenal azotaemia, leads to a markedly elevated blood urea while serum creatinine remains comparatively stable.
Restrictive Red Blood Cell Transfusion Strategy
Both NICE clinical guidelines (CG141) and the British Society of Gastroenterology (BSG) mandate a restrictive transfusion strategy :
Standard Threshold: Once major haemorrhage is controlled, transfuse red cells when haemoglobin is below 70 g/L , targeting a post-transfusion haemoglobin of 70–90 g/L (NICE NG24 restrictive thresholds; BSG uses the same 70 g/L trigger). During massive haemorrhage, transfusion follows the major haemorrhage protocol and clinical response, not a number.
Cardiovascular Disease Exception: In patients with known, significant ischaemic heart disease or active acute coronary syndrome, use a transfusion trigger of <80 g/L , targeting 80–100 g/L .
Caution
Avoid Over-Transfusion: Liberal transfusion (targeting Hb >90–100 g/L) significantly increases portal venous pressure, disrupts early clot formation, provokes rebound bleeding, and increases mortality in both variceal and non-variceal haemorrhage.
Coagulopathy & Reversal Protocols
Platelets: Transfuse adult therapeutic doses of platelets only if actively bleeding with a platelet count <50 × 10⁹/L .
Fresh Frozen Plasma (FFP): Administer FFP (15 mL/kg) if the INR is >1.5 in the context of active major haemorrhage.
Warfarin Reversal: Administer Prothrombin Complex Concentrate (PCC) (e.g. Beriplex, 25–50 IU/kg) and intravenous Vitamin K (phytomenadione 5–10 mg) for immediate reversal in life-threatening bleeding.
DOAC Reversal: Specific reversal agents include idarucizumab for dabigatran, or andexanet alfa (or PCC 50 IU/kg) for factor Xa inhibitors (apixaban, rivaroxaban).
3. Pre-Endoscopy vs Post-Endoscopy Risk Stratification
Clinical risk scores differentiate patients requiring urgent critical care and immediate endoscopy from those suitable for outpatient management.
Glasgow-Blatchford Bleeding Score (GBS)
The Glasgow-Blatchford Score is calculated pre-endoscopy using routine bedside clinical and laboratory parameters. It assesses the risk of requiring intervention (transfusion, endoscopic therapy, or surgery) or dying.
- Clinical Parameter Parameter Value GBS Points Allocated
- Blood Urea (mmol/L) 6.5 – 7.9 2
- Blood Urea (mmol/L) 8.0 – 9.9 3
- Blood Urea (mmol/L) 10.0 – 24.9 4
- Blood Urea (mmol/L) ≥ 25.0 6
- Haemoglobin (Men) 120 – 129 g/L 1
- Haemoglobin (Men) 100 – 119 g/L 3
- Haemoglobin (Men) < 100 g/L 6
- Haemoglobin (Women) 100 – 119 g/L 1
- Haemoglobin (Women) < 100 g/L 6
- Systolic Blood Pressure 100 – 109 mmHg 1
- Systolic Blood Pressure 90 – 99 mmHg 2
- Systolic Blood Pressure < 90 mmHg 3
- Pulse Rate ≥ 100 bpm 1
- Clinical Presentation Melaena 1
- Clinical Presentation Syncope 2
- Co-morbidities Hepatic Disease 2
- Co-morbidities Cardiac Failure 2
Important
Clinical Action Threshold for GBS:
GBS = 0: Extremely low risk (<0.5% intervention or mortality). These patients do not require hospital admission and can be safely managed in the outpatient setting with elective endoscopy.
GBS > 0: Requires hospital admission, hemodynamic monitoring, and inpatient endoscopy.
Full Rockall Score
The Full Rockall Score is calculated post-endoscopy to quantify the risk of rebleeding and all-cause mortality. It integrates:
- Age: (<60 = 0; 60–79 = 1; ≥80 = 2)
- Shock: (No shock = 0; Tachycardia HR >100 = 1; Hypotension SBP <100 = 2)
- Co-morbidity: (None = 0; CAD/Heart failure = 2; Renal failure/Liver failure/Metastatic malignancy = 3)
- Endoscopic Diagnosis: (Mallory-Weiss/No lesion = 0; PUD/Erosions = 1; Upper GI malignancy = 2)
Stigmata of Recent Haemorrhage: (Clean base/Flat spot = 0; Blood in stomach/Adherent clot/Visible spurting vessel = 2)
A post-endoscopy Rockall score <3 denotes low risk of death (<5%), whereas a score ≥8 confers a mortality exceeding 40%.
4. Suspected Variceal Haemorrhage Protocol
Any patient presenting with upper GI bleeding who exhibits stigmata of chronic liver disease (spider naevi, palmar erythema, jaundice, ascites, caput medusae, splenomegaly) or a history of cirrhosis must be treated as a suspected variceal haemorrhage immediately.
Pharmacological Pre-Endoscopic Management
Intravenous Terlipressin: Administer 2 mg IV bolus immediately upon suspicion, continued at 1–2 mg every 4–6 hours (or QDS) for up to 48–72 hours until haemostasis is secure. Terlipressin is a synthetic vasopressin analogue that induces splanchnic vasoconstriction, reducing portal venous inflow and decreasing variceal pressure. Adverse effects: Peripheral ischaemia, bradycardia, coronary vasospasm, and hyponatraemia.
Prophylactic Broad-Spectrum Antibiotics: Administer intravenous ceftriaxone (1 g once daily) or co-amoxiclav prior to endoscopy. Cirrhotic patients experiencing UGIB are at extreme risk of bacterial translocation and spontaneous bacterial peritonitis. Prophylactic antibiotics significantly reduce rebleeding rates and decrease all-cause mortality.
Proton Pump Inhibitors: Routine pre-endoscopic PPI infusions are not indicated for variceal bleeding and should be withheld until diagnostic endoscopy clarifies the mucosal pathology.
Endoscopic & Interventional Rescue
First-Line Endoscopy: Must be performed within 24 hours of presentation (or emergently once resuscitated if persistently hypotensive). The definitive treatment of choice for oesophageal varices is Endoscopic Variceal Band Ligation (EVBL) . Sclerotherapy is reserved only when band ligation is technically unfeasible.
Gastric Variceal Bleeding: Managed with endoscopic injection of N-butyl-2-cyanoacrylate tissue glue (histoacryl) mixed with Lipiodol.
Balloon Tamponade (Sengstaken-Blakemore Tube): Employed strictly as a temporary bridge to definitive care in catastrophic, uncontrolled exsanguinating bleeding. The gastric balloon is inflated with 200–250 mL of air and gentle traction is applied to compress the gastro-oesophageal junction. The oesophageal balloon is inflated only if bleeding continues. Due to risk of pressure necrosis and oesophageal rupture, tamponade must never exceed 24 hours. The patient must be endotracheally intubated prior to tube insertion to prevent pulmonary aspiration.
Transjugular Intrahepatic Portosystemic Shunt (TIPS): Radiological creation of a low-resistance channel between the hepatic vein and an intrahepatic branch of the portal vein using an expandable covered stent. Indicated as "pre-emptive/early TIPS" within 72 hours for high-risk patients (Child-Pugh C or Child-Pugh B with active bleeding) or as salvage rescue for failed endoscopic haemostasis.
Secondary Prevention: Once stabilized, commence oral non-selective beta-blockers ( carvedilol 6.25–12.5 mg daily or propranolol) alongside repeated elective outpatient band ligation every 2 to 4 weeks until varices are completely obliterated.
5. Non-Variceal Peptic Ulcer Haemorrhage
Peptic ulcer disease accounts for half of all UGIB cases. Management focuses on targeted endoscopic haemostasis and acid suppression.
Forrest Classification & Endoscopic Stigmata
Forrest Ia (Arterial spurting) & Ib (Oozing haemorrhage): High rebleeding risk (~80%); mandates dual endoscopic haemostasis.
Forrest IIa (Non-bleeding visible vessel): High rebleeding risk (~50%); mandates dual endoscopic haemostasis.
Forrest IIb (Adherent clot): Intermediate rebleeding risk; endoscopic clot removal and underlying vessel treatment.
Forrest IIc (Flat pigmented spot) & III (Clean ulcer base): Low rebleeding risk (<5%); no endoscopic intervention required; early oral re-feeding and discharge.
Dual-Modality Endoscopic Haemostasis
Monotherapy with adrenaline injection is inadequate because adrenaline provides only temporary vasospasm and local mechanical tamponade without definitive vessel thrombosis. Guidelines strictly mandate dual-modality therapy :
- Adrenaline (1:10,000) injection PLUS
- Mechanical modality: Endoscopic hemoclips (through-the-scope clips or over-the-scope clips), OR
Thermal contact coagulation: Bipolar electrocoagulation or heater probe coagulation.
High-Dose Post-Endoscopy Proton Pump Inhibitors
Following successful endoscopic haemostasis for high-risk ulcer stigmata (Forrest Ia–IIa), administer high-dose intravenous PPI therapy (e.g. omeprazole 80 mg IV bolus followed by 8 mg/hour continuous infusion for 72 hours , or high-dose intermittent IV omeprazole 40 mg twice daily). Suppressing gastric acidity to maintain intragastric pH >6 prevents pepsin activation and promotes platelet aggregation and fibrin clot stabilization.
6. Dyspepsia & Peptic Ulcer Disease: Investigation & Eradication
Dyspepsia refers to a complex of upper abdominal symptoms including epigastric pain or discomfort, heartburn, acid regurgitation, early satiety, and nausea.
NICE NG12 Upper GI Cancer Criteria
NICE NG12 ( Suspected cancer: recognition and referral ) uses the suspected cancer pathway (the referral route formerly called the "2-week wait"):
Urgent direct-access upper GI endoscopy (within 2 weeks): dysphagia at any age, or age 55 or over with weight loss AND any of upper abdominal pain, reflux or dyspepsia.
Suspected cancer pathway referral (consider): an upper abdominal mass consistent with stomach cancer.
Non-urgent direct-access endoscopy (consider), age 55 or over: treatment-resistant dyspepsia; upper abdominal pain with low haemoglobin; raised platelet count with nausea, vomiting, weight loss, reflux, dyspepsia or upper abdominal pain; or nausea or vomiting with weight loss, reflux, dyspepsia or upper abdominal pain.
Uncomplicated Dyspepsia (No Red Flags, NICE CG184)
Review medicines (stop NSAIDs or aspirin if possible) and offer lifestyle advice (weight loss, smoking cessation, alcohol reduction, avoiding late meals).
Offer either "test and treat" for H. pylori (carbon-13 urea breath test or stool antigen) or a full-dose PPI for 4 weeks ; if symptoms continue, try the other approach.
H. pylori positive: 7-day triple eradication therapy (PPI plus amoxicillin plus clarithromycin or metronidazole). Retest only if symptoms persist or there is a specific indication (for example a peptic ulcer).
Helicobacter pylori Diagnostic Testing
Carbon-13 Urea Breath Test (¹³C-UBT) or Stool Antigen Test (SAT): High sensitivity and specificity (>95%).
Critical Pre-Test Requirement: Patients must stop taking proton pump inhibitors for at least 2 weeks and antibiotics for at least 4 weeks prior to breath or stool testing. Failure to withhold these agents suppresses bacterial load and causes false-negative results.
Serology (Serum IgG): Demonstrates past exposure; cannot differentiate active infection from successfully treated infection. Not recommended for clinical management.
First-Line 7-Day H. pylori Eradication Triple Therapy
In the UK, first-line eradication therapy consists of a 7-day twice-daily oral regimen :
Patient Subgroup Recommended 7-Day Twice-Daily Regimen
Non-Penicillin Allergic • Proton Pump Inhibitor (e.g. Omeprazole 20 mg BD or Lansoprazole 30 mg BD); • Amoxicillin 1 g BD ; • Clarithromycin 500 mg BD (or Metronidazole 400 mg BD)
Penicillin Allergic • Proton Pump Inhibitor (e.g. Omeprazole 20 mg BD); • Clarithromycin 500 mg BD ; • Metronidazole 400 mg BD
Reflux, Barrett's Oesophagus, Hiatus Hernia & Upper GI Cancer
Gastro-oesophageal reflux disease (NICE CG184): heartburn and regurgitation; offer lifestyle advice and a full-dose PPI for 4 weeks (8 weeks for severe oesophagitis), then the lowest dose that controls symptoms. Alarm features (dysphagia, weight loss, anaemia, persistent vomiting, age 55 or over with new symptoms) need endoscopy under NICE NG12.
Barrett's oesophagus: columnar metaplasia of the lower oesophagus from chronic reflux; it is the precursor of oesophageal adenocarcinoma . Patients have PPI treatment and endoscopic surveillance; dysplasia is treated endoscopically (resection and ablation).
Hiatus hernia: sliding hernias (most common) worsen reflux; rolling (para-oesophageal) hernias can twist or strangulate (gastric volvulus) and are repaired surgically if symptomatic.
Oesophageal cancer: adenocarcinoma of the lower third (reflux, Barrett's, obesity) or squamous cell carcinoma of the upper and middle thirds (smoking, alcohol). It presents with progressive dysphagia (solids, then liquids) and weight loss; dysphagia at any age needs urgent direct-access endoscopy .
Gastric cancer: adenocarcinoma linked to H. pylori , smoking and diet; presents with dyspepsia, weight loss, anaemia, vomiting or an epigastric mass, and sometimes a left supraclavicular node ( Virchow's node, Troisier's sign ).